Want to see IN:PANACEABIO full AI Analyst Report?
PANACEABIO Stock Chart & Stats
₹440.65
-₹8.10(-1.84%)
At close: 4:00 PM EDT
₹440.65
-₹8.10(-1.84%)
Day’s Range― - ―
52-Week Range₹293.10 - ₹647.50
Previous CloseN/A
Volume125.06K
Average Volume (3M)7.58K
Market Cap
₹22.54B
Enterprise Value₹17.33K
Total Cash (Recent Filing)₹744.00M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)―
Beta1.08
Next Earnings
Nov 14, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.56%
Share Statistics
EPS (TTM)-1.16
Shares Outstanding61,250,744
10 Day Avg. Volume4,978
30 Day Avg. Volume7,583
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)2.16
Price to Sales (P/S)2.82
P/FCF Ratio-49.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue RecoveryRevenue has recovered substantially from FY2023 levels and continued to grow in FY2026, indicating renewed commercial traction across the company’s pharmaceutical and vaccine-related portfolio. Sustained top-line expansion can improve operating leverage and support reinvestment over the next several quarters.
Conservative Balance SheetVery low leverage and sizable, stable equity provide financial flexibility while the company works to restore profitability. A conservative balance sheet reduces debt-servicing pressure, improves resilience during uneven earnings periods, and preserves capacity to fund products, operations, or strategic initiatives.
Improved Operating Cash FlowThe return to positive operating cash flow in FY2026 is an important improvement in the underlying cash conversion trend. If maintained, it could reduce reliance on the balance sheet and provide greater support for ongoing pharmaceutical and biotechnology operations, although consistency remains important.
Bears Say
Persistent UnprofitabilityThe company’s revenue recovery has not yet translated into sustainable profits, with both EBIT and net income still negative in FY2026. Continued losses can constrain internally funded growth, weaken returns on the stable equity base, and limit financial progress unless margins improve.
Negative Free Cash FlowPersistently negative free cash flow indicates that the business has absorbed cash over multiple years despite the latest improvement in operating cash flow. Continued cash consumption can increase dependence on existing balance-sheet resources and reduce flexibility for investment, expansion, or shareholder returns.
Volatile Earnings QualityThe absence of consistent margins and the failure of the FY2022 profit to persist point to an earnings model that remains unstable. Such volatility makes future profitability less predictable and means revenue growth may not reliably create durable earnings or returns without operational improvement.
Panacea Biotec Limited News
PANACEABIO FAQ
What was Panacea Biotec Limited’s price range in the past 12 months?
Panacea Biotec Limited lowest stock price was ₹293.10 and its highest was ₹647.50 in the past 12 months.
What is Panacea Biotec Limited’s market cap?
Panacea Biotec Limited’s market cap is ₹22.54B.
When is Panacea Biotec Limited’s upcoming earnings report date?
Panacea Biotec Limited’s upcoming earnings report date is Nov 14, 2026 which is in 53 days.
How were Panacea Biotec Limited’s earnings last quarter?
Panacea Biotec Limited released its earnings results on Aug 13, 2026. The company reported ₹0.376 earnings per share for the quarter.
Is Panacea Biotec Limited overvalued?
According to Wall Street analysts Panacea Biotec Limited’s price is currently Overvalued.
Does Panacea Biotec Limited pay dividends?
Panacea Biotec Limited pays a Annually dividend of ₹0.75 which represents an annual dividend yield of 0.56%. See more information on Panacea Biotec Limited dividends here
What is Panacea Biotec Limited’s EPS estimate?
Panacea Biotec Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Panacea Biotec Limited have?
Panacea Biotec Limited has 61,250,744 shares outstanding.
What happened to Panacea Biotec Limited’s price movement after its last earnings report?
Panacea Biotec Limited reported an EPS of ₹0.376 in its last earnings report. Following the earnings report the stock price went up 3.5%.
Which hedge fund is a major shareholder of Panacea Biotec Limited?
Currently, no hedge funds are holding shares in IN:PANACEABIO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Panacea Biotec Limited
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India, with operations segmented into Vaccines and Formulations. The company's pharmaceutical offerings comprise proprietary medicines targeting diverse medical fields such as pain management, diabetes, cardiovascular health, oncology, renal disease, osteoporosis, anti-tubercular therapy, and gastro-intestinal care. In addition to these, Panacea Biotec develops and distributes vaccines for conditions like anthrax, dengue, and Japanese encephalitis, among others. The firm maintains a robust global presence, exporting its goods to over 30 countries, including key markets such as the United States, Germany, the Russian Federation, Sri Lanka, and the Philippines. Notably, Panacea Biotec has established significant strategic alliances, including a partnership with the Russian Direct Investment Fund for the manufacture of the Sputnik-V COVID-19 vaccine. It also collaborates with the Coalition for Epidemic Preparedness Innovations (CEPI) and the Translational Health Science and Technology Institute (THSTI) to pioneer vaccine candidates designed to combat SARS-CoV-2 variants and other beta coronaviruses.
Technical Analysis
Biocon Limited
―
Concord Biotech Ltd.
―
Piramal Pharma Limited
―
Supriya Lifescience Limited
―
Syngene International Ltd.
―